Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis.

in Maturitas (1997), 26(1), 63-71

Postmenopausal osteoporosis is a progressive disorder characterized by a decreased bone mass and increased susceptibility to fractures. Several investigations have suggested that one of the mechanisms ... [more ▼]

Postmenopausal osteoporosis is a progressive disorder characterized by a decreased bone mass and increased susceptibility to fractures. Several investigations have suggested that one of the mechanisms through which estrogen prevents bone loss was a modulation on secretion or release of various cytokines that are known to influence bone remodeling, even if some recent data have challenged this hypothesis. However, in established osteoporosis, the possibility that enhanced cytokines activity may account for the progression of this disease remains unclear and controversial. We sought here to determine whether production of IL-1 beta, IL-6, TNF-alpha, IFN-gamma, GM-CSF and LIF, after direct stimulation in whole blood, was different in healthy (n = 30) or osteoporotic postmenopausal women (n = 24) and whether lumbar bone density (1-BMD) correlated with the values of cytokine production observed in these conditions. A significant difference was observed between the osteoporotic and control subjects for IL-1 beta (p < 0.0001), IL-6 (p < 0.001) and TNF-alpha (p = 0.027) productions, the values being higher in the osteoporotic women. No significant differences between the groups were observed for IFN-gamma (p = 0.51), GM-CSF (p = 0.70) or LIF (p = 0.97). In the whole population, statistically significant negative correlations were observed between lumbar BMD and IL-1 beta (r = -0.46) (p < 0.0005), IL-6 (r = -0.50) (p < 0.0001) and TNF-alpha (r = -0.39) (p < 0.005) production while no such correlations were observed for IFN-gamma, GM-CSF or LIF. In conclusion, the study of cytokine production by immune cells cultured in autologous whole blood suggests that in women more than 10 years past the menopause and presenting a decrease in lumbar bone density corresponding to the new WHO definition of "osteoporosis', production of IL-1 beta, IL-6 and TNF-alpha is still increased compared to controls matched for age and ovarian function, while no differences are reported for IFN-gamma, GM-CSF or LIF production. [less ▲]

Etude in vitro des effets des résidus insaponifiables d’avocat et de soja (IAS) sur le métabolisme des chondrocytes humains

in Revue du Rhumatisme (1997), 64(11), 822

Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide 1 chain of type I collagen. Application in an enzyme immunoassay and comparison to Crosslaps TM Elisa

in Scandinavian Journal of Clinical & Laboratory Investigation (1997), 57

Essai comparatif de deux antalgiques, la floctafénine et le paracétamol, au cours de l’arthrose des membres inférieurs

in Revue du Rhumatisme (1997), 64(5), 349-355

Optimizing the treatment of Paget’s disease of bone

in Revue du Rhumatisme (English ed.) (1997), 64(4), 207-209

Drug consumption in a Belgian subpopulation of peaple older than 45 years

Conference (1997)

Etude de l’applicabilité de la démarche de Santé communautaire aux structures de prévention de l’O.N.E.

Report (1997)

Fidélité du patient au médecin généraliste et consommation des soins de santé : une approche multivariée. Dans le cadre du projet “ Dossier médical ” de l’I.N.A.M.I., Rapport final de synthèse

Report (1997)

Parathyroid Hormone in the Treatment of Involutional Osteoporosis: Back to the Future

in Osteoporosis International (1997), 7(Suppl 3), 163-8

Influence de l'association du nomegestrol acetate sur l'amélioration de la qualité de vie induite par une estrogenotherapie chez la femme ménopausée

in Contraception, Fertilite, Sexualité (1992) (1996), 24(11), 847-51

Estrogen replacement therapy in postmenopausal women is followed by several benefits including a prompt improvement of quality of life. Due to uterine proliferation induced by prolonged estrogen intake ... [more ▼]

Estrogen replacement therapy in postmenopausal women is followed by several benefits including a prompt improvement of quality of life. Due to uterine proliferation induced by prolonged estrogen intake, progestogens are usually associated, on a cyclical basis, in hormonal replacement therapy prescribed to non-hysterectomized women. Persistence of the beneficial effect of estrogen on quality of life, during progestogens intake, was never investigated. We evaluated, through a specific and previously validated questionnaire, the changes in quality of life observed in 351 women recently menopaused, after 6 months of hormonal replacement therapy associating 24 days of estrogens and 12 days of administration of a non androgenic progestogen: nomegestrol acetate. Patients were randomized within two therapeutic groups in which evaluation of quality of life was performed either during the administration of estrogen alone or during administration of estrogen and progestogen. In the two groups, hormonal replacement therapy was followed by a significant improvement (P < 0,001) in quality of life and no significant difference was observed between the changes observed during estrogen or estrogen-progestogen administration. Quality of life indices measured after 6 months of hormonal replacement therapy are within the same range than values previously described in eugonadal women. We conclude that improvement of quality of life induced by estrogen replacement therapy remains unchanged during cyclical administration of nomegestrol acetate. [less ▲]